$ cat ./records/gates-foundation-backed-consortium-publishes-complete-genome-of-t-2005.txt
Gates Foundation-Backed Consortium Publishes Complete Genome of Theileria parva — Opening Path to Designed ECF Vaccines
[RECORD.TXT] · cat --full
A Gates Foundation-supported international consortium — including ILRI, the Wellcome Sanger Institute, the USDA, and the NIH — published the complete genome sequence of Theileria parva in Science magazine in 2005. The genome enabled researchers to map all candidate antigens for a subunit vaccine that could replace the live ECF-ITM approach, reducing biosafety risks and enabling mass production. The publication is regarded as the foundational step toward a designed, commercialisable ECF vaccine.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Founded Target Malaria — the world's first gene drive research consortium targeting malaria mosquitoes
Next →
Gates Foundation total assets surpass $29 billion — the largest private charitable foundation in history
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.